

Our Thanks



^b
UNIVERSITÄT
BERN



Our special thanks goes:




To all the speakers for their contribution to the scientific success of this meeting

To the Medical Faculty of the University of Bern, University Hospital Bern, the Bern Center for Precision Medicine, Witec AG, Bucher Biotec AG, Miltenyi Biotec GmbH, CELLnTEC Advanced Cell System AG, Carl Zeiss AG and Nikon AG for their financial support.

We also specifically thank the SCRM/TCBM Strategic Board for supporting our activities:

Prof. Eliane J. Müller
Prof. Hans-Uwe Simon
Prof. Mark Rubin
Prof. Adrian Ochsenbein
Prof. Daniel Surbek
Prof. Gabriela Baerlocher

The SCRM Steering Committee
www.stemcellsbern.ch



A collaboration between Insel Spital,
Medical and Vetsuisse Faculty

The SCRM Steering Committee:

Prof. Eliane J. Müller
Prof. Volker Enzmann
Prof. Benjamin Gantenbein
Dr. Amiq Gazdhar
PD Dr. Carsten Riether
Prof. Daniel Surbek
Prof. Emeritus Thomas Krause

Program

Annual meeting 2019 Innovation in personalized cell therapy

SCRM Platform, University of Bern

November 8th 2019

Haus der Universität, Schlösslistrasse 5, 3012 Bern

Program

12h30-13h00	Registration
13h00-13h15	Welcome – Prof. Eliane J. Müller Inselspital University Hospital Bern, Medical & Vetsuisse Faculty University of Bern
	<u>Organoids</u>
13h15-13h45	PD Dr. Marianna Kruithof-de Julio , University Hospital of Urology, Bern <i>Organoids and the Translational research of Urological Cancers</i>
13h45-14h15	Dr. Marco Alves , Institute of Virology and Immunology (IVI), University of Bern <i>Modeling virus infection of the human central nervous system using stem cell-derived cerebral organoids</i>
	<u>Cell Therapies</u>
14h15-14h45	Dr. Eric Roos , Global Director of Strategic Alliances for Cell and Gene Therapy, Thermo Fisher Scientific Dr. Roland Leathers , Senior Manager Strategic Alliances, Thermo Fisher Scientific <i>Cell Therapy from an Industry Perspective</i>
14h45-15h15	Coffee break
15h15-15h45	Prof. Volker Enzmann , University Hospital of Ophthalmology, Bern <i>Experimental Therapies in Regenerative Neuroscience: an overview</i>
15h45-16h15	PD Dr. Urban Novak , University Hospital of Medical Oncology, Bern <i>CAR-T cells as an option for the treatment of lymphomas</i>
	<u>Panel Discussion</u>
16h15-17h00	Guests: Prof. Dr. Carlo Largiadèr , Member of the BCPM management board Dr. Eric Roos and Dr. Roland Leathers , Thermo Fisher Scientific
17h00-18h00	Networking Aperitif

Papers

PD Dr. Marianna Kruithof-de Julio

Karkampouna S, et al, CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma, J. Pathol, 2018

Dr. Marco Alves

Vielle NJ, et al; The human upper respiratory tract epithelium is susceptible to flaviviruses, Front Microbiol, 2019

Schögler A, et al, Modulation of the unfolded protein response pathway as an antiviral approach in airway epithelial cells, Antiviral Res, 2019

Vielle NJ, et al, Silent infection by African and Asian strains of Zika virus in human dendritic cells, Sci Rep, 2018

García-Nicolás O, et al, Targeting of the nasal mucosa by Japanese encephalitis virus for non-vector-borne transmission, J. Virol, 2018

Alves MP, et al, Research models and tools for the identification of antivirals and therapeutics against Zika virus infection, Viruses, 2018

Baud D, et al, Zika virus: a new treatath to human reproduction, Am J Reprod Immunol, 2017

Prof. Volker Enzmann

Conedera F, Quintela Pousa AM, Tschopp M, Mercader N, Enzmann V: Retinal microglia signaling affects Müller cell behavior in the zebrafish following laser injury induction, Glia, 2019

PD Dr. Urban Novak

Stephen J, et al, Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma, NEJM, 2018

Locke FL, et al, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 2019